Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Main billing specialty: interventional radiology.
Medicare fee-for-service tumor & fibroid embolization cases in the 37 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 34 | 1,753+3.4%/yr | +3.4%/yr | 0.50.9× | 40% | 4,240 in 2030+16%/yr |
| New York | 22 | 1,661+10%/yr | +10%/yr | 0.91.5× | 48% | 3,360 in 2030+12%/yr |
| Florida | 29 | 1,301+2.9%/yr | +2.9%/yr | 0.61.0× | 55% | 3,590 in 2030+18%/yr |
| Texas | 20 | 1,239+2.9%/yr | +2.9%/yr | 0.61.0× | 63% | 3,140 in 2030+17%/yr |
| Pennsylvania | 19 | 908−0.7%/yr | −0.7%/yr | 0.71.1× | 27% | 1,830 in 2030+12%/yr |
| Virginia | 12 | 902+21%/yr | +21%/yr | 0.91.5× | 55% | 2,310 in 2030+17%/yr |
| North Carolina | 11 | 795+10%/yr | +10%/yr | 0.81.4× | 63% | 1,900 in 2030+16%/yr |
| Arizona | 11 | 723+24%/yr | +24%/yr | 1.01.7× | 78% | 1,640 in 2030+15%/yr |
| Maryland | 12 | 701+17%/yr | +17%/yr | 0.81.3× | 80% | 1,270 in 2030+10%/yr |
| Massachusetts | 12 | 677+16%/yr | +16%/yr | 0.71.2× | 46% | 1,170 in 2030+9.5%/yr |
| Illinois | 14 | 674+3.6%/yr | +3.6%/yr | 0.50.8× | 49% | 1,750 in 2030+17%/yr |
| Michigan | 7 | 565+12%/yr | +12%/yr | 0.71.1× | 78% | 1,300 in 2030+15%/yr |
| Missouri | 6 | 541+7.4%/yr | +7.4%/yr | 0.91.5× | 56% | 860 in 2030+8.1%/yr |
| Tennessee | 13 | 482+8.1%/yr | +8.1%/yr | 0.71.2× | 71% | 1,670 in 2030+23%/yr |
| Colorado | 4 | 415+7.6%/yr | +7.6%/yr | 0.91.4× | 70% | 820 in 2030+12%/yr |
| Ohio | 7 | 370+1.9%/yr | +1.9%/yr | 0.30.6× | 67% | 1,280 in 2030+23%/yr |
| Oregon | 6 | 355+8.7%/yr | +8.7%/yr | 0.91.4× | 30% | 460 in 2030+4.5%/yr |
| Washington | 8 | 333+2.3%/yr | +2.3%/yr | 0.40.7× | 39% | 490 in 2030+6.6%/yr |
| Wisconsin | 4 | 296+1.8%/yr | +1.8%/yr | 0.50.9× | 0% | 330 in 2030+1.9%/yr |
| New Jersey | 4 | 287+0.9%/yr | +0.9%/yr | 0.30.5× | 22% | 820 in 2030+19%/yr |
| Indiana | 5 | 282+1.3%/yr | +1.3%/yr | 0.40.7× | 61% | 580 in 2030+13%/yr |
| Georgia | 5 | 259−8.1%/yr | −8.1%/yr | 0.30.5× | 64% | 920 in 2030+23%/yr |
| Kentucky | 1 | 248+17%/yr | +17%/yr | 0.50.9× | 79% | 1,090 in 2030+28%/yr |
| Minnesota | 4 | 239+0.6%/yr | +0.6%/yr | 0.50.9× | 45% | 380 in 2030+7.9%/yr |
| South Carolina | 7 | 207−3.3%/yr | −3.3%/yr | 0.30.5× | 46% | 820 in 2030+26%/yr |
| Alabama | 5 | 198+0.2%/yr | +0.2%/yr | 0.50.8× | 68% | 810 in 2030+26%/yr |
| Mississippi | 6 | 194+19%/yr | +19%/yr | 0.50.9× | 36% | 380 in 2030+12%/yr |
| Oklahoma | 2 | 185+1.4%/yr | +1.4%/yr | 0.40.6× | 22% | 180 in 2030−0.6%/yr |
| Iowa | 3 | 178+14%/yr | +14%/yr | 0.40.7× | 0% | 260 in 2030+6.8%/yr |
| Louisiana | 3 | 167−2.6%/yr | −2.6%/yr | 0.40.7× | 37% | 260 in 2030+7.6%/yr |
| Arkansas | 3 | 165−1.3%/yr | −1.3%/yr | 0.40.7× | 73% | 740 in 2030+29%/yr |
| Kansas | 3 | 164+3.8%/yr | +3.8%/yr | 0.40.7× | 65% | 580 in 2030+24%/yr |
| Connecticut | 3 | 119−5.9%/yr | −5.9%/yr | 0.40.6× | 0% | 170 in 2030+6.1%/yr |
| Nebraska | 2 | 116+16%/yr | +16%/yr | 0.40.8× | 23% | 210 in 2030+10%/yr |
| South Dakota | 2 | 101+20%/yr | +20%/yr | 0.81.3× | 42% | 180 in 2030+9.6%/yr |
| District of Columbia | 3 | 100−4.1%/yr | −4.1%/yr | 1.62.7× | 87% | 160 in 2030+7.9%/yr |
| Utah | 2 | 100−2.9%/yr | −2.9%/yr | 0.50.8× | 38% | 190 in 2030+11%/yr |
Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 70 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 29 companies. The most active:
Product codes: KRD (device, vascular, for promoting embolization), QVG (embolization agent, vascular). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +53 pts since 2019, to 56%.
The 10 busiest do 47% of the cases CMS names in California; 22 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Breast biopsy & localization | 3,675 | 218,500−1.8%/yr | −1.8%/yr | 243,500 in 2030+1.8%/yr |
| Tumor ablation | 63 | 8,642+0.4%/yr | +0.4%/yr | 12,000 in 2030+5.6%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 27 companies reported engagement with surgeons in the covered states worth $16M in consulting, speaking, meals and travel tied to these products, about $52K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.